Description
This variant is denoted VHL c.347T>G at the cDNA level, p.Leu116Arg (L116R) at the protein level, and results in the change of a Leucine to an Arginine (CTT>CGT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. VHL Leu116Arg was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Leucine and Arginine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. VHL Leu116Arg occurs at a position where amino acids with properties similar to Leucine are tolerated across species and is located in the beta-domain and is involved in binding to CCT complex (Yuen 2009, UniProt). While computational modeling has predicted VHL Leu116Arg to be functionally significant (Rajasekaran 2008), in-house in silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether VHL Leu116Arg is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
| # | Sample | Method | Observation |
|---|
| Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
|---|
| 1 | germline | yes | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |
